Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating Costs and Expenses:
General and administrative	$ 1,197,000	$ 1,098,000	$ 3,876,000	$ 3,297,000
Research and development	914,000	4,144,000	4,152,000	9,156,000
Total Operating Costs and Expenses	2,111,000	5,242,000	8,028,000	12,453,000
Loss from Operations	(2,111,000)	(5,242,000)	(8,028,000)	(12,453,000)
Other Income :
Interest income	0	92,000	44,000	217,000
Total Other Income	0	92,000	44,000	217,000
Net Loss	(2,111,000)	(5,150,000)	(7,984,000)	(12,236,000)
Net Loss Attributable to Non-controlling Interest	(8,000)	(30,000)	(50,000)	(73,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(2,103,000)	(5,120,000)	(7,934,000)	(12,163,000)
Preferred Stock Dividends, Income Statement Impact				(185,000)
Net Loss Attributable to Common Stockholders	$ (2,686,000)	$ (5,253,000)	$ (9,438,000)	$ (12,934,000)
Net Loss Per Share - Basic and Dilutive	$ (0.14)	$ (0.31)	$ (0.52)	$ (0.79)
Weighted average number of shares outstanding during the period - Basic and Dilutive	19,398,339	16,805,257	18,302,585	16,313,326
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (64,000)	$ (63,000)	$ (189,000)	$ (185,000)
Series B Preferred Stock [Member]
Other Income :
Net Loss Attributable to Non-controlling Interest	0	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	0	0
Preferred Stock Dividends, Income Statement Impact	$ (519,000)	$ (70,000)	$ (1,315,000)	$ (585,000)